CareDx Income from Continuous Operations 2013-2024 | CDNA
CareDx income from continuous operations from 2013 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
| CareDx Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024 | $53 |
| 2023 | $-190 |
| 2022 | $-77 |
| 2021 | $-31 |
| 2020 | $-19 |
| 2019 | $-22 |
| 2018 | $-47 |
| 2017 | $-56 |
| 2016 | $-40 |
| 2015 | $-14 |
| 2014 | $1 |
| 2013 | $-4 |
| 2012 | $-5 |
| CareDx Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024-12-31 | $78 |
| 2024-09-30 | $-7 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-17 |
| 2023-12-31 | $-118 |
| 2023-09-30 | $-23 |
| 2023-06-30 | $-25 |
| 2023-03-31 | $-24 |
| 2022-12-31 | $-18 |
| 2022-09-30 | $-17 |
| 2022-06-30 | $-22 |
| 2022-03-31 | $-20 |
| 2021-12-31 | $-16 |
| 2021-09-30 | $-12 |
| 2021-06-30 | $-2 |
| 2021-03-31 | $-1 |
| 2020-12-31 | $-4 |
| 2020-09-30 | $-3 |
| 2020-06-30 | $-7 |
| 2020-03-31 | $-6 |
| 2019-12-31 | $-5 |
| 2019-09-30 | $-2 |
| 2019-06-30 | $-8 |
| 2019-03-31 | $-8 |
| 2018-12-31 | $-4 |
| 2018-09-30 | $-20 |
| 2018-06-30 | $-14 |
| 2018-03-31 | $-9 |
| 2017-12-31 | $-32 |
| 2017-09-30 | $-14 |
| 2017-06-30 | $-4 |
| 2017-03-31 | $-6 |
| 2016-12-31 | $-16 |
| 2016-09-30 | $-4 |
| 2016-06-30 | $-10 |
| 2016-03-31 | $-10 |
| 2015-12-31 | $-5 |
| 2015-09-30 | $-3 |
| 2015-06-30 | $-3 |
| 2015-03-31 | $-2 |
| 2014-12-31 | $0 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $-1 |
| 2013-12-31 | $-1 |
| 2013-09-30 | $-1 |
| 2013-06-30 | $-1 |
| 2013-03-31 | $-1 |
| 2012-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.835B | $0.334B |
| CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. | |||